There are 2 broad categories of funding that support biomedical product development. The categories differ based on whether or not the current owner of the company gives up any ownership or control of the company in exchange for funding. Non-dilutive funding means the owner of the company does not lose any control to the funder while dilutive funding means the funders receive some part of the company (e.g. ownership, future profits) in exchange for providing the funding.
Non-Dilutive Funding
Overview of small business grants (SBIR/STTR)
- SBIR Tutorials - A range of online tutorials, including both video and multimedia options, through the SBIR/STTR website. These tutorials over all the bases within the application process, as well as offering advice to more seasoned SBIR/STTR awardees.
- Catalyzing the Next Generation of Healthcare Technologies and New Medicines - 52 minute overview video by Jennifer Shieh, PhD (NIH Small Business Coordinator and Program Director) provided by the UC Center for Accelerated Innovation and UCLA Clinical and Translational Science Institute. Gives an overview of SBIR/STTR from the NHLBI perspective.
Competitive Commercialization Plan and SBIR Phase II Application
Dilutive Funding